Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Charlotte

CHARLOTTE HAYNES

Charlotte joined MPE as Scientific and Patient Information Manager in January 2026.

Charlotte holds a PhD and BSc in Experimental Psychology from the University of Sussex, and a Postgraduate Certificate in Public Health from the University of Manchester. She has over 20 years of experience in healthcare research, evidence synthesis, and scientific communication.

Before joining MPE, Charlotte worked for 13 years at the National Institute for Health and Care Excellence (NICE), a public body that develops independent, evidence-based guidance to improve health and social care in England. She also worked for eight years as Research and Projects Lead at a UK NHS foundation trust hospital. In these roles, she worked at the interface of science, policy, and communication, ensuring that evidence was accurately interpreted and translated into clear, practical recommendations for health and social care professionals, commissioners and managers, patients, service users and carers.

Charlotte has a strong commitment to patient-centred communication and to ensuring that information is inclusive and accessible for all patient populations. She currently lives in the North West of England. She speaks English fluently and French at an upper-intermediate level.

 

Recent Posts

MPE AGM Welcome to our newest members and congratulations to our newly elected board

31 March 2026

At the MPE Annual General Meeting on Tuesday, 31 March, we were pleased to welcome four new member organisations into the MPE community and to confirm the results of our…

Read more

AF3M recognised by French Prime Minister

27 March 2026

The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association…

Read more

Launch of Myeloma Forward

26 March 2026

Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland…

Read more

MPE visits plasma donation centre

23 March 2026

Last week MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria. Plasma donations are needed from people to produce immunoglobulin…

Read more
Webinar generic drugs graphic

Join our webinar “The generics market in Europe and implications for cancer treatment and care”

5 March 2026

Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET.…

Read more

Highlights from the Myeloma Cure Summit

25 February 2026

Myeloma has always been an incurable cancer which is becoming increasingly chronic with treatment advances and access. Whilst the community remains cautious talking about myeloma as a curable cancer there…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.